{"id":19977,"date":"2026-08-05T15:22:15","date_gmt":"2026-08-05T19:22:15","guid":{"rendered":"https:\/\/defeatduchenne.ca\/?p=19977"},"modified":"2026-08-05T15:42:10","modified_gmt":"2026-08-05T19:42:10","slug":"defeat-duchenne-canada-new-paper-highlights-the-importance-of-expanding-vamorolone-access-for-canadians-with-duchenne","status":"publish","type":"post","link":"https:\/\/defeatduchenne.ca\/fr\/defeat-duchenne-canada-new-paper-highlights-the-importance-of-expanding-vamorolone-access-for-canadians-with-duchenne\/","title":{"rendered":"Vaincre Duchenne Canada : un nouvel article souligne l\u2019importance d\u2019\u00e9largir l\u2019acc\u00e8s au vamorolone pour les Canadiens vivant avec la dystrophie musculaire de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Defeat Duchenne Canada is pleased to share the publication of \u201cExpanding Vamorolone Treatment Access for Canadians with Duchenne\u201d in the <em>Canadian Journal of Neurological Sciences<\/em>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Supported by Defeat Duchenne Canada, the paper brings together Canadian neuromuscular specialists, paediatric endocrinologists and patient advocates to examine the evolving treatment landscape for Duchenne muscular dystrophy (DMD) and the importance of timely and equitable access to treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In October 2025, Health Canada approved AGAMREE\u00ae (vamorolone), the first approved therapy for DMD in Canada for people living with DMD aged four years of age and older.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">While the Health Canada approval of vamorolone represents an important advancement in the Canadian DMD landscape, its approval is only the first step. Ensuring that eligible individuals can access AGAMREE\u00ae through provincial and territorial drug plans in a timely and equitable way is critical. The paper also highlights the importance of maintaining access to other treatment options, including deflazacort, and building a more coordinated approach to treatment access for DMD and other rare diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This publication is an important contribution to the conversation about what Canadians living with DMD need today and how we can build a stronger, more accessible treatment landscape for the future. Our sincere thanks to the paper\u2019s authors and all those working to advance treatment options for the DMD community.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For Defeat Duchenne Canada, access to treatment is a key priority. We will continue working with families, clinicians, researchers, governments, and other partners to support timely, equitable access to therapies and care for DMD.&nbsp;<\/p>\n\n\n\n<div style=\"height:36px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/defeatduchenne.ca\/wp-content\/uploads\/2026\/08\/expanding-vamorolone-treatment-access-for-canadians-with-duchenne-muscular-dystrophy.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Read the full paper<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Un nouvel article soutenu par Vaincre Duchenne Canada examine comment le Canada peut assurer \u00e0 la communaut\u00e9 Duchenne un acc\u00e8s rapide et \u00e9quitable aux traitements, en s\u2019appuyant sur le point de vue de sp\u00e9cialistes, d\u2019endocrinologues et de d\u00e9fenseurs des patients.<\/p>","protected":false},"author":16,"featured_media":18141,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_psn_rejection_reason":"","footnotes":""},"categories":[72,78],"tags":[153,85,84],"class_list":["post-19977","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-advocacy","category-ddc","tag-advocacy","tag-defeat-duchenne-canada","tag-vamorolone"],"acf":[],"_links":{"self":[{"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/posts\/19977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/comments?post=19977"}],"version-history":[{"count":3,"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/posts\/19977\/revisions"}],"predecessor-version":[{"id":19982,"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/posts\/19977\/revisions\/19982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/media\/18141"}],"wp:attachment":[{"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/media?parent=19977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/categories?post=19977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/defeatduchenne.ca\/fr\/wp-json\/wp\/v2\/tags?post=19977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}